Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19

• Main Authors: Kun Wang (Author), Haijun Li (Author), Youyun Li (Author), Fengyan Xu (Author), Zhongyi Sun (Author), Yuting Yang (Author), Jufang Huang (Author), Xiaoxin Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

IntroductionLeritrelvir (RAY1216) acts as a main protease inhibitor that hinders the cleavage of viral precursor proteins, thereby inhibiting virus replication of SARS-CoV-2). This antiviral mechanism has shown significant efficacy against the novel coronavirus. Preclinical studies have demonstrated...